Injective (INJ) Drops 8.9% Amid Broad Crypto Selloff

Understanding Injective's (INJ) Recent Price Decline

Injective (INJ) experienced a significant drop primarily due to a broader crypto and DeFi selloff driven by macro risk-off and a sharp Bitcoin reversal, rather than any Injective-specific negative news.

Market Wide Risk Off And Bitcoin Reversal

The past day has seen a clear risk-off turn across both crypto and traditional markets.

1. Total crypto market cap decreased from approximately $2.82 trillion to $2.72 trillion within 24 hours, a decline of about 3.6%. Open interest in derivatives dropped more than 10% over the same period, indicating broad deleveraging rather than a single-coin shock.
2. Bitcoin slid from near $84,800 to the low $81,000s within a day, influenced by mixed Tesla and Meta earnings, geopolitical tensions in the Middle East, and a spike in oil prices. This pushed investors out of risk assets, with Bitcoin dropping around 3 to 4% and roughly $400 million of crypto long liquidations in 24 hours.
3. This scenario is a classic example of macro-driven risk-off, where earnings disappointment in high-profile AI-related stocks, rising oil prices due to Iran-related fears, and heightened geopolitical risk weigh on global stocks, pushing investors toward safer assets and spilling over into crypto, particularly higher beta altcoins.

DeFi And Altcoins Underperforming

Within the broad selloff, DeFi and altcoins have been hit harder than Bitcoin, which is the segment where Injective operates.

1. A DeFi index fell about 5.6% while a broader large cap index dropped roughly 2.5%, indicating that decentralized finance tokens are leading the downside in this leg, not just following Bitcoin one for one.
2. Major DeFi and alt-related names such as Uniswap, Sui, Ethena, and others fell in the mid-single-digit range during the session when Bitcoin slipped back below $82,000, underscoring a sector-wide rotation out of higher beta protocols as risk appetite shrinks.
3. Injective is a DeFi-focused protocol token tied to derivatives and trading infrastructure. Historically, tokens in this category tend to amplify market moves in both directions: they can outperform in risk-on phases and underperform when traders de-risk and close leveraged positions.

Injective Specific Price Path And News

Examining INJ’s data and recent headlines helps determine whether anything project-specific caused the move.

1. Over the last 24 hours, INJ is down about 8.92%, with price moving from roughly $8.71 to about $7.92 on solid but not extreme 24-hour volume near $124 million. The steepest leg of that move occurred between late Wednesday night and early Thursday UTC, when INJ slipped from around $8.71 to about $8.15, which aligns with the period when Bitcoin and the broader market reversed lower and liquidations spiked.
2. Recent Injective-related coverage over the past days has focused on structural or positive developments: cumulative burn statistics from its auction and community programs, a proposal for a staked INJ style ETF product, and a memorandum of understanding around using a KRW stable asset for institutional real-world asset settlement on Injective. These are long-term design and growth items and are not framed as negative shocks or immediate trading catalysts. There are no reports of hacks, exploits, exchange delistings, governance failures, or unexpected unlocks tied to INJ in this window.
3. Volume in INJ over the day stayed in a relatively tight band (roughly $123 million to $136 million on the 1-hour snapshots), with no singular blowout spike that would normally flag an isolated event such as a listing removal or protocol scare. The grind lower after the initial drop is characteristic of a token tracking sector beta and macro flows instead of reacting to an Injective-only problem.

Conclusion

INJ’s roughly 8.9% 24-hour decline, and the additional few percentage points of underperformance over the last 19 hours, align closely with a broad risk-off move in crypto and equities where Bitcoin retreated from the mid $80,000s, total crypto market cap fell around 3 to 4%, derivatives open interest shrank, and DeFi and altcoins led the downside.

Against this backdrop, Injective appears to be moving as a high beta DeFi asset rather than reacting to any clear, coin-specific catalyst such as a hack, delisting, or adverse protocol news. The best available evidence points to macro and sector-wide forces as the drivers of the recent INJ price movement.